Date: 18 August – 17 November 2023, every Friday
Time: 6pm – 9pm (SGT)
Format: Hybrid
(Online via Zoom OR Face-to-face at MD1 Tahir Foundation Building, National University of Singapore)
Research growth and the related exponential rate of accumulation of publications have escalated the need for effective and efficient methods to synthesize the evidence base for evaluating health technologies. This course is designed to provide participants with the skills to generate good quality evidence for conducting health technology assessments (HTA) that meet the needs of decision makers.
This course is designed to provide participants with the skills to generate good quality evidence for use in health technology assessment (HTA). Upon completion, participants will be able to:
An electronic Certificate of Participation will be awarded to participants who meet a minimum of 75% attendance.
 | Course coordinator: A/Prof Wee Hwee-Lin Associate Professor, Saw Swee Hock School of Public Health, National University of Singapore A/Prof Wee is an Associate Professor in the Saw Swee Hock School of Public Health at the National University of Singapore. Her current work involves understanding patient preferences for high- cost treatments, public preferences for pre-emptive pharmacogenetic testing and factors associated with well-being among Singaporeans. |
 | Lecturer: Dr Charles Zheng Qishi APAC Regional Market Access, Roche Diagnostics Asia Pacific Dr Zheng was medically trained and currently oversees APAC Regional Market Access in Roche Diagnostics Asia Pacific and a member of the Cochrane Singapore . His research interests lie in systematic review and meta-analysis for both diagnostic and interventional studies, health economic modelling and statistical analysis. Formerly, he was a Senior Epidemiologist with Singapore Clinical Research Institute, collaborating with local clinicians and researchers on conducting clinical trials, real-world studies, and health services research. |
 | Lecturer: Dr David Bin-Chia Wu Regional Director, Real World Evidence & Health Economics (Asia Pacific) Dr David Wu Bin-Chia is the Regional Director of Real World Evidence & Health Economics at The Janssen Pharmaceutical Companies of Johnson & Johnson in Singapore and is also an Adjunct Senior Lecturer of Monash University Malaysia. His diverse research activities centred around generating evidence through economic evaluations based on various economic modelling and biostatistical approaches to inform healthcare policy decision-making. He has collaborated extensively with international institutions including the World Health Organization, the United States Agency for International Development, Centers for Disease Control in Taiwan, the Malaysian Ministry of Health, Ministry of Health (the Philippines), and has provided expert advice and technical support to many pharmaceutical companies in health economics and outcomes research. |
 | Lecturer: Mr Adrien Gras Head of Market Access & HEOR, APAC, Ipsos Mr Adrien Gras is highly experienced leader in global pharmaceutical and medical device market access and HEOR. Adrien currently leads a team of experts in the field across the APAC region. He has been involved in all aspects of product development, from R&D activities such as drug target identification and drug discovery, pipeline commercial strategy, economic modelling, government reimbursement negotiation, and lifecycle management. He has published peer-reviewed journals and manuals in the fields of biochemistry, health economics and policy. Adrien was awarded a BSc in Biotechnology from Imperial College before completing an MRes in Structural Biology at Birkbeck College. |
 | Lecturer: Adjunct A/Prof Ng Kwong Hoe Principal Head (HTA), Agency for Care Effectiveness, Ministry of Health |
 | Lecturer: Dr Gunjeet Kaur Postdoctoral Fellow, Saw Swee Hock School of Public Health, National University of Singapore Dr Gunjeet Kaur is a public health professional, with a doctoral degree in Health Economics on “Role of Health Technology Assessment in Priority Setting for Health Care in India” from Department of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Her research experience and interests include evidence synthesis, costing, out-of-pocket payments, cost-effectiveness analysis and distributional cost-effectiveness analysis studies in health care. Previously, she was working as Senior Researcher/consultant at Bergen School of Ethics and Priority Setting, Norway. Currently, she is a postdoctoral fellow in HTA in the Saw Swee Hock School of Public Health, National University of Singapore. |
| Category | Fee* |
| Student/LMICs¹ | S$1425.60 |
| NUS Staff/Partners | S$2376.00 |
| Public Sector | S$3564.00 |
| Private Sector | S$5940.00 |
Remarks:
*Prices stated above are in Singapore Dollars (SGD) and are inclusive of 8% Singapore Goods and Services Tax. The University reserves the right to review and adjust the course fees and make changes to the programme structure and requirements as necessary and accordingly without prior notice.
